Qiagen N.V. (QGEN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Qiagen N.V.

NYSE•Healthcare•Diagnostics & Research

$43.47-0.39(-0.01%)Pre-market

Market Cap

$9.03B

P/E

22.1x

P/S

4.3x

P/B

2.7x

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

How this company scores

GoodMetricSide Score: 71/100

Strongest: Profitability (23/25); weakest: Balance Sheet & Red Flags (13/25).

Profitability23/25

Growth17/25

Balance Sheet & Red Flags13/25

Cash & Earnings Quality18/25

Strengths

Strong marginsLow leverageCash-backed earningsConsistent free cash flow

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 20.2x5y range 20.2x – 125.5x

Currently below its 20-quarter median.

P/S · 3.9x5y range 3.9x – 5.9x

Currently near its 20-quarter median.

P/B · 2.5x5y range 2.5x – 4.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Leverage Risk

Watch

Debt-to-equity has risen 92.0% recently — increasing financial risk even if the current ratio is manageable.

Price & Volume

Market Cap $9.03B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $2.10B
Q. Revenue: $535.04M
TTM EBITDA: $736.16M
TTM Op. Income: $532.09M
Q. Op. Income: $132.40M
TTM Net Income: $409.32M
Q. Net Income: $103.40M
EPS: N/A
Shares Out.: $207.83M

$2.10B in TTM revenue grew 3.0% YoY, reaching $535.04M last quarter. TTM EBITDA of $736.16M and TTM operating income of $532.09M show growth is flowing through to the bottom line. TTM net income of $409.32M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 26.6%
Op. Margin: 24.7%
Net Margin: 19.3%

Op. margin of 24.7% is up 1.9% YoY — cost efficiency is improving. Net margin at 19.3% Over the past year, operating margin is up 8% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 20.2x
P/S Ratio: 3.9x
P/B Ratio: 2.5x

At 20.2x P/E, the stock trades within typical market levels. P/S of 3.9x and P/B of 2.5x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has fallen for 6 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $5.89B
Cash: $768.50M
Long-Term Debt: $1.63B
Book Value: $3.36B
D/E Ratio: 0.5
Debt/EBITDA: 11.4

With $5.89B in assets and $1.63B in long-term debt, D/E is 0.5and book value is $3.36B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 92% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

TTM Free Cash Flow: $447.70M
FCF Margin: 21.3%
FCF / Net Income: 1.1

TTM FCF of $447.70M. The FCF / Net Income ratio of 1.1x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 10% — an improving trend.